PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Cyclopharm Limited (CYC.AX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

AU000000CYC5

Sector

Healthcare

IPO Date

Jan 19, 2007

Highlights

Market Cap

A$230.05M

EPS (TTM)

-A$0.10

Total Revenue (TTM)

A$12.27M

Gross Profit (TTM)

-A$1.55M

EBITDA (TTM)

-A$6.58M

Year Range

A$1.33 - A$2.50

Target Price

A$2.90

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of A$10,000 in Cyclopharm Limited, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%20.00%40.00%60.00%SeptemberOctoberNovemberDecember2025February
45.26%
16.45%
CYC.AX (Cyclopharm Limited)
Benchmark (^GSPC)

Returns By Period

Cyclopharm Limited had a return of 30.60% year-to-date (YTD) and 16.29% in the last 12 months. Over the past 10 years, Cyclopharm Limited had an annualized return of 22.48%, outperforming the S&P 500 benchmark which had an annualized return of 11.21%.


CYC.AX

YTD

30.60%

1M

-0.96%

6M

45.26%

1Y

16.29%

5Y*

14.24%

10Y*

22.48%

^GSPC (Benchmark)

YTD

2.90%

1M

3.70%

6M

10.94%

1Y

22.18%

5Y*

12.41%

10Y*

11.21%

*Annualized

Monthly Returns

The table below presents the monthly returns of CYC.AX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202540.06%30.60%
2024-9.09%3.14%-0.55%-2.51%-18.00%17.77%-7.10%-14.01%12.59%-7.57%19.57%-5.65%-17.66%
202320.51%6.38%21.74%15.38%-4.76%0.00%15.00%4.35%18.16%-30.39%2.54%-4.70%65.42%
20227.62%-17.56%12.71%-8.24%-13.34%-21.92%38.92%0.71%0.33%-4.93%-2.22%-11.36%-28.19%
202119.20%-11.75%-2.28%9.55%-7.83%-34.37%-2.35%0.31%0.60%19.16%-9.04%-9.39%-34.07%
20201.70%-19.16%3.69%32.00%16.67%-9.09%6.07%-7.07%75.27%-15.77%18.23%4.17%113.89%
20198.60%-1.66%-7.20%13.30%5.26%13.07%-4.76%-3.22%-14.81%1.30%-1.29%2.61%7.67%
2018-3.16%4.35%23.43%-8.47%-6.95%-0.50%-9.49%2.21%15.24%-0.95%8.09%-2.65%17.46%
20174.39%-11.57%-2.98%-4.33%21.29%-11.97%0.00%-6.10%-1.97%33.33%-5.99%1.06%6.68%
201613.48%3.38%-11.45%19.57%21.87%25.65%42.86%-21.43%9.58%-1.66%-23.30%0.55%77.42%
20155.39%52.52%12.21%-9.91%45.06%-16.66%9.08%-18.34%10.22%-4.70%7.86%-5.47%87.39%
20140.00%-16.04%-0.00%0.00%0.00%0.00%-0.00%4.79%29.51%22.86%-14.30%-6.67%11.98%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of CYC.AX is 55, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of CYC.AX is 5555
Overall Rank
The Sharpe Ratio Rank of CYC.AX is 5454
Sharpe Ratio Rank
The Sortino Ratio Rank of CYC.AX is 5454
Sortino Ratio Rank
The Omega Ratio Rank of CYC.AX is 5454
Omega Ratio Rank
The Calmar Ratio Rank of CYC.AX is 5757
Calmar Ratio Rank
The Martin Ratio Rank of CYC.AX is 5656
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Cyclopharm Limited (CYC.AX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for CYC.AX, currently valued at 0.23, compared to the broader market-2.000.002.004.000.231.59
The chart of Sortino ratio for CYC.AX, currently valued at 0.86, compared to the broader market-6.00-4.00-2.000.002.004.000.862.16
The chart of Omega ratio for CYC.AX, currently valued at 1.11, compared to the broader market0.501.001.502.001.111.29
The chart of Calmar ratio for CYC.AX, currently valued at 0.23, compared to the broader market0.002.004.006.000.232.40
The chart of Martin ratio for CYC.AX, currently valued at 0.82, compared to the broader market0.0010.0020.0030.000.829.79
CYC.AX
^GSPC

The current Cyclopharm Limited Sharpe ratio is 0.23. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Cyclopharm Limited with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00SeptemberOctoberNovemberDecember2025February
0.23
2.04
CYC.AX (Cyclopharm Limited)
Benchmark (^GSPC)

Dividends

Dividend History

Cyclopharm Limited provided a 0.00% dividend yield over the last twelve months, with an annual payout of A$0.00 per share.


0.00%0.20%0.40%0.60%0.80%1.00%A$0.00A$0.00A$0.00A$0.01A$0.01A$0.012015201620172018201920202021202220232024
Dividends
Dividend Yield
PeriodTTM2024202320222021202020192018201720162015
DividendA$0.00A$0.00A$0.01A$0.01A$0.01A$0.01A$0.01A$0.01A$0.01A$0.01A$0.01

Dividend yield

0.00%0.00%0.52%0.85%0.61%0.40%0.85%0.90%1.05%1.10%0.96%

Monthly Dividends

The table displays the monthly dividend distributions for Cyclopharm Limited. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025A$0.00A$0.00A$0.00
2024A$0.00A$0.00A$0.00A$0.00A$0.00A$0.00A$0.00A$0.00A$0.00A$0.00A$0.00A$0.00A$0.00
2023A$0.00A$0.00A$0.01A$0.00A$0.00A$0.00A$0.00A$0.00A$0.01A$0.00A$0.00A$0.00A$0.01
2022A$0.00A$0.00A$0.00A$0.01A$0.00A$0.00A$0.00A$0.00A$0.01A$0.00A$0.00A$0.00A$0.01
2021A$0.00A$0.00A$0.00A$0.01A$0.00A$0.00A$0.00A$0.00A$0.01A$0.00A$0.00A$0.00A$0.01
2020A$0.00A$0.00A$0.01A$0.00A$0.00A$0.00A$0.00A$0.00A$0.01A$0.00A$0.00A$0.00A$0.01
2019A$0.00A$0.00A$0.00A$0.01A$0.00A$0.00A$0.00A$0.00A$0.01A$0.00A$0.00A$0.00A$0.01
2018A$0.00A$0.00A$0.00A$0.01A$0.00A$0.00A$0.00A$0.00A$0.01A$0.00A$0.00A$0.00A$0.01
2017A$0.00A$0.00A$0.01A$0.00A$0.00A$0.00A$0.00A$0.00A$0.01A$0.00A$0.00A$0.00A$0.01
2016A$0.00A$0.00A$0.00A$0.01A$0.00A$0.00A$0.00A$0.00A$0.01A$0.00A$0.00A$0.00A$0.01
2015A$0.01A$0.00A$0.00A$0.01

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%SeptemberOctoberNovemberDecember2025February
-36.59%
-1.51%
CYC.AX (Cyclopharm Limited)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Cyclopharm Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Cyclopharm Limited was 95.42%, occurring on Mar 22, 2013. Recovery took 1897 trading sessions.

The current Cyclopharm Limited drawdown is 36.59%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-95.42%Jan 22, 20071558Mar 22, 20131897Sep 17, 20203455
-70.85%Jan 28, 2021355Jun 23, 2022
-25.57%Sep 18, 202030Oct 29, 202025Dec 3, 202055
-13.26%Dec 7, 202023Jan 11, 20214Jan 15, 202127
-5.16%Jan 18, 20213Jan 20, 20213Jan 25, 20216

Volatility

Volatility Chart

The current Cyclopharm Limited volatility is 19.78%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


5.00%10.00%15.00%20.00%25.00%30.00%SeptemberOctoberNovemberDecember2025February
19.78%
3.48%
CYC.AX (Cyclopharm Limited)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Cyclopharm Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Cyclopharm Limited.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab